153190-29-5

U-74389G (intravenous injection; 10 mg/kg; once daily; 6 d) treatment shows significant anti-inflammatory activity related to its ability to reduce colonic TNF-α, CMDI score, and improve weight change^[2].
U-74389G (intravenous injection; 15 or 30 mg/kg) treatment significantly protects against lipopolysaccharide-induced lethality, reduces hypotension, ameliorates liver function, decreases plasma nitrite levels, restores the hyporeactivity of aortic rings to their control values and inhibits the activity of inducible NO synthase in the liver and in the aorta^[3].